Skip to main content

Table 3 Conditions and symptoms treated with cannabis according to gender and age among individuals who reported self-medication with cannabis in an online survey in Quebec from November 2020 to January 2021 (n = 489)

From: A description of self-medication with cannabis among adults with legal access to cannabis in Quebec, Canada

Treated conditions

Gender (missing = 3; 16 participants with “other gender” not stratified)

Age (years) (missing = 4)

Total

Men (n = 233)

Women (n = 237)

p-value

≤ 34 (n = 251)

> 34 (n = 234)

p-value

Psychological disorders

199 (85.41)

202 (85.23)

0.96

226 (90.04)

189 (80.77)

0.0037

415 (85.57)

 Anxiety

155 (66.52)

176 (74.26)

0.06

196 (78.09)

148 (63.253)

0.0003

344 (70.93)

 Depression

95 (40.77)

78 (32.91)

0.07

113 (45.02)

71 (30.34)

0.0009

184 (37.94)

 Insomnia

136 (58.37)

129 (54.43)

0.39

148 (58.96)

126 (53.85)

0.25

274 (56.49)

 PTSDa

33 (14.16)

40 (16.88)

0.41

43 (17.13)

34 (14.53)

0.43

77 (15.88)

 ADHDb

75 (32.19)

47 (19.83)

0.002

68 (27.09)

56 (23.93)

0.42

124 (25.57)

 Shyness

38 (16.31)

14 (5.91)

0.0003

43 (17.13)

11 (4.70)

< 0.0001

54 (11.13)

Somatic disorders

168 (72.10)

184 (77.64)

0.17

179 (71.31)

182 (77.78)

0.103

361 (74.43)

 Chronic non-cancer pain

126 (54.08)

126 (53.16)

0.84

115 (46.82)

144 (61.54)

0.0005

259 (53.40)

 Headaches/migraines

61 (26.18)

74 (31.22)

0.23

86 (34.26)

52 (22.22)

0.003

138 (28.45)

 Bowel disease

22 (9.44)

33 (13.92)

0.13

20 (7.97)

35 (14.96)

0.015

55 (11.34)

 Muscle spasticity

47 (20.17)

33 (13.92)

0.07

36 (14.34)

45 (19.23)

0.14

81 (16.70)

 Nausea/vomiting (unrelated to chemotherapy)

15 (6.44)

30 (12.66)

0.02

28 (11.16)

20 (8.55)

0.33

48 (9.90)

 Endometriosis or other gynecological disorder

NA

36 (15.19)

-

27/125 (21.60)

8/112 (7.14)

0.0017

35/237 (14.77)

Unclassified

 Loss of appetite

46 (19.74)

41 (17.30)

0.50

57 (22.71)

35 (14.96)

0.029

92 (18.97)

 Sexual disorder

14 (6.01)

19 (8.02)

0.39

20 (7.97)

13 (5.56)

0.29

33 (6.80)

Other conditionsc

45 (19.31)

32 (13.50)

0.09

31 (12.35)

50 (21.37)

0.0078

81 (16.70)

  1. Comparisons between groups were made using chi-square tests and p-value calculated. A p-value < 0.05 was considered as statistically significant
  2. aPTSD Post-traumatic stress disorder
  3. bADHD Attention deficit hyperactivity disorder
  4. cOther conditions include cancer pain (n = 3), cancer (n = 7), palliative care (n = 1), schizophrenia/psychosis (n = 3), nausea due to chemotherapy, obesity (n = 7), diabetes (n = 8), weight loss (n = 12), alcohol or opioid withdrawal (n = 15), tic disorder/Gilles de la Tourette’s syndrome (n = 3), tremor/Parkinson disease (n = 7), bladder disorder/incontinence (n = 8), asthma (n = 1), autism (n = 1), congestion (n = 1), trigger finger (n = 1), gender dysphoria (n = 1), rash (n = 1), nicotine withdrawal symptom (n = 2), hypothyroidism (n = 1), snoring (n = 1), chronic obstructive pulmonary disease (n = 1), psoriasis (n = 10), Ehlers-Danlos syndrome (n = 1), restless legs syndrome (n = 3), borderline personality disorder (n = 2), shingles (n = 1), suicidal ideation (n = 1), Meniere’s disease (n = ), itchy skin (n = 1), mental/ocular fatigue (n = 1)
Back to article page

Journal of Cannabis Research

ISSN: 2522-5782